906 related articles for article (PubMed ID: 15870918)
41. VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL.
Knauth K; Cartwright E; Freund S; Bycroft M; Buchberger A
J Biol Chem; 2009 Apr; 284(16):10514-22. PubMed ID: 19228690
[TBL] [Abstract][Full Text] [Related]
42. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C.
Kibel A; Iliopoulos O; DeCaprio JA; Kaelin WG
Science; 1995 Sep; 269(5229):1444-6. PubMed ID: 7660130
[TBL] [Abstract][Full Text] [Related]
43. [Somatic mutations of VHL gene and HIF-1alpha expression in primary renal clear cell carcinomas].
Guo HF; Gong K; Zou SM; Zhang ZW; Liu XY; Na X; Wu G; Na YQ
Zhonghua Wai Ke Za Zhi; 2004 Feb; 42(4):196-200. PubMed ID: 15062033
[TBL] [Abstract][Full Text] [Related]
44. Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.
Miller F; Kentsis A; Osman R; Pan ZQ
J Biol Chem; 2005 Mar; 280(9):7985-96. PubMed ID: 15611064
[TBL] [Abstract][Full Text] [Related]
45. Effect of radiation and ibuprofen on normoxic renal carcinoma cells overexpressing hypoxia-inducible factors by loss of von Hippel-Lindau tumor suppressor gene function.
Palayoor ST; Burgos MA; Shoaibi A; Tofilon PJ; Coleman CN
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4158-64. PubMed ID: 15217953
[TBL] [Abstract][Full Text] [Related]
46. von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME.
Tedesco L; Elguero B; Pacin DG; Senin S; Pollak C; Garcia Marchiñena PA; Jurado AM; Isola M; Labanca MJ; Palazzo M; Yankilevich P; Fuertes M; Arzt E
Cell Death Dis; 2019 Mar; 10(4):266. PubMed ID: 30890701
[TBL] [Abstract][Full Text] [Related]
47. Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein.
Nakamura E; Abreu-e-Lima P; Awakura Y; Inoue T; Kamoto T; Ogawa O; Kotani H; Manabe T; Zhang GJ; Kondo K; Nosé V; Kaelin WG
Am J Pathol; 2006 Feb; 168(2):574-84. PubMed ID: 16436671
[TBL] [Abstract][Full Text] [Related]
48. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.
Raval RR; Lau KW; Tran MG; Sowter HM; Mandriota SJ; Li JL; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ
Mol Cell Biol; 2005 Jul; 25(13):5675-86. PubMed ID: 15964822
[TBL] [Abstract][Full Text] [Related]
49. Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma.
Sorrell AD; Lee S; Stolle C; Ellenhorn J; Grix A; Kaelin WG; Weitzel JN
Clin Genet; 2011 Jun; 79(6):539-45. PubMed ID: 20560986
[TBL] [Abstract][Full Text] [Related]
50. Molecular cloning and characterization of the von Hippel-Lindau-like protein.
Qi H; Gervais ML; Li W; DeCaprio JA; Challis JR; Ohh M
Mol Cancer Res; 2004 Jan; 2(1):43-52. PubMed ID: 14757845
[TBL] [Abstract][Full Text] [Related]
51. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.
Knebelmann B; Ananth S; Cohen HT; Sukhatme VP
Cancer Res; 1998 Jan; 58(2):226-31. PubMed ID: 9443397
[TBL] [Abstract][Full Text] [Related]
52. RSUME inhibits VHL and regulates its tumor suppressor function.
Gerez J; Tedesco L; Bonfiglio JJ; Fuertes M; Barontini M; Silberstein S; Wu Y; Renner U; Páez-Pereda M; Holsboer F; Stalla GK; Arzt E
Oncogene; 2015 Sep; 34(37):4855-66. PubMed ID: 25500545
[TBL] [Abstract][Full Text] [Related]
53. The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing.
Kaelin WG
Cold Spring Harb Symp Quant Biol; 2005; 70():159-66. PubMed ID: 16869749
[TBL] [Abstract][Full Text] [Related]
54. Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas.
Cuevas Y; Hernández-Alcoceba R; Aragones J; Naranjo-Suárez S; Castellanos MC; Esteban MA; Martín-Puig S; Landazuri MO; del Peso L
Cancer Res; 2003 Oct; 63(20):6877-84. PubMed ID: 14583486
[TBL] [Abstract][Full Text] [Related]
55. VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations.
Rechsteiner MP; von Teichman A; Nowicka A; Sulser T; Schraml P; Moch H
Cancer Res; 2011 Aug; 71(16):5500-11. PubMed ID: 21715564
[TBL] [Abstract][Full Text] [Related]
56. Molecular targets from VHL studies into the oxygen-sensing pathway.
Maynard MA; Ohh M
Curr Cancer Drug Targets; 2005 Aug; 5(5):345-56. PubMed ID: 16101382
[TBL] [Abstract][Full Text] [Related]
57. Identification of novel VHL targets that are associated with the development of renal cell carcinoma.
Abdulrahman M; Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Wiesener MS; Richards FM; Johnson CM; Latif F; Maher ER
Oncogene; 2007 Mar; 26(11):1661-72. PubMed ID: 17001320
[TBL] [Abstract][Full Text] [Related]
58. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells.
Gunaratnam L; Morley M; Franovic A; de Paulsen N; Mekhail K; Parolin DA; Nakamura E; Lorimer IA; Lee S
J Biol Chem; 2003 Nov; 278(45):44966-74. PubMed ID: 12944410
[TBL] [Abstract][Full Text] [Related]
59. The HIF and other quandaries in VHL disease.
Tarade D; Ohh M
Oncogene; 2018 Jan; 37(2):139-147. PubMed ID: 28925400
[TBL] [Abstract][Full Text] [Related]
60. [Von Hippel-Lindau disease].
Shuin T; Ashida S; Yao M; Kanno H
Nihon Rinsho; 2000 Jul; 58(7):1448-54. PubMed ID: 10921322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
